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Abstract
Background: Incidentally found thyroid lesions are frequently detected in patients undergoing
FDG-PET/CT. The aim of this study was to investigate the prevalence of incidentally found thyroid
lesions in patients undergoing FDG-PET/CT and determine the risk for thyroid cancer.
Methods: FDG-PET/CT was performed on 3,379 patients for evaluation of suspected or known
cancer or cancer screening without any history of thyroid cancer between November 2003 and
December 2005. Medical records related to the FDG-PET/CT findings including maximum
SUV(SUVmax) and pattern of FDG uptake, US findings, FNA, histopathology received by operation
were reviewed retrospectively.
Results: Two hundred eighty five patients (8.4%) were identified to have FDG uptake on FDG-
PET/CT. 99 patients with focal or diffuse FDG uptake underwent further evaluation. The cancer
risk of incidentally found thyroid lesions on FDG-PET/CT was 23.2% (22/99) and the cancer risks
associated with focal and diffuse FDG uptake were 30.9% and 6.4%. There was a significant
difference in the SUVmax between the benign and malignant nodules (3.35 ± 1.69 vs. 6.64 ± 4.12; P
< 0.001). There was a significant correlation between the SUVmax and the size of the cancer.
Conclusion: The results of this study suggest that incidentally found thyroid lesions by FDG-PET/
CT, especially a focal FDG uptake and a high SUV, have a high risk of thyroid malignancy. Further
diagnostic work-up is needed in these cases.
Background
Incidentalomas of the thyroid are defined as thyroid
lesions identified by radiological imaging, such as ultra-
sonography (US), computed tomography (CT) and mag-
netic resonance imaging (MRI) for nonthyroid disease
[1,2]. In an autopsy series, the prevalence of thyroid nod-
ules was approximately 50% [3]. Despite the high preva-
lence of nodules, the annual incidence of palpable thyroid
nodules is estimated to be 0.1% in North America [4].
Therefore, most thyroid nodules are identified inciden-
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tally than by palpation. While a number of incidentally
found thyroid nodules have been identified, the risk of
thyroid cancer in these nodules is not well known.
Positron emission tomography (PET)/CT using 18F-fluor-
odeoxyglucose (FDG) is increasingly performed for stag-
ing or localization of metastatic disease in patients with
various kinds of malignancies. The uptake of the FDG in
the normal thyroid gland is homogenous and of low
intensity; the normal thyroid gland is usually not visual-
ized on a FDG-PET. [5,6] Focal or diffuse FDG uptake in
the thyroid is often seen as an incidental finding. Some
studies have reported that the incidence of thyroid inci-
dentalomas with increased FDG uptake is 1.2% – 2.3% on
PET examinations [5,7-9]. The risk of malignancy in these
studies ranged from 26.7% to 50%.
The recently developed FDG-PET/CT provides the advan-
tages of two modalities; the anatomic information is pro-
vided by the spiral CT and the functional information by
the FDG-PET. This combined approach has resulted in a
significant improvement in both anatomic localization
and diagnostic accuracy [10-12]. Since the introduction of
the FDG-PET/CT, the vast majority of systems are now
produced as combined FDG-PET/CT rather than FDG-
PET.
The purpose of this study was to evaluate our institutional
experience with incidentally identified thyroid lesions by
FDG-PET/CT in suspected or known cancer patients as
well as in patients undergoing health screening, and to
determine the risk of thyroid malignancy in these
patients.
Methods
Patients
From November 2003 to December 2005, 3,416 patients
underwent FDG-PET/CT in Kangnam St. Mary's Hospital,
Seoul, Korea. Among them, 37 patients who were studied
because of thyroid cancer were excluded from the study
population. Thus, 3,379 patients were included in this
analysis. FDG-PET/CT was performed on 666 patients
without a previous history of cancer for cancer screening
and 2,713 patients received scanning for suspected or
known nonthyroid cancer.
PET/CT Method
For the FDG PET/CT examination, Biograph LSO (Sie-
mens Medical Solutions; Knoxville, TN) integrated with a
dual-section helical CT scanner (Somatom Emotion; Sie-
mens) was used. All subjects fasted for at least 6 hours
(blood glucose level < 130 mg/dL) before their FDG PET/
CT examinations. Image acquisition for the whole body
scan started about 60 min after the intravenous adminis-
tration of 550 MBq of F-18 FDG. Whole body emission
scans consisted of 7–8 bed positions for 2 min at each
position. In this study, a focal thyroid lesion was defined
as a focally increased 18F-FDG uptake on the PET images
or focal a lesion on the CT images (Fig. 1). A diffuse thy-
roid lesion was defined as 18F-FDG uptake in the whole
thyroid gland (Fig. 2). The maximum SUV (SUVmax) val-
ues were obtained for each patient with abnormal thyroid
uptake on the FDG-PET/CT. Two experienced nuclear
physicians reviewed the images retrospectively.
Diagnosis and Management of Incidentally Found Thyroid 
Lesions on PET/CT
Experienced radiologists, who were aware of the FDG-
PET/CT findings before US, performed high-resolution
ultrasonography (US). US features associated with benign
thyroid lesions are purely cystic nodules, hyperechoic
nodules, sharp margination, coarse calcification and
peripheral vascularity [13]. US features associated with
malignancy are microcalcifications, hypoechoic nodules,
irregular margins, tall than wide shape and central vascu-
larization [13,14]. A fine needle aspiration (FNA) was per-
formed in patients with abnormal findings on
ultrasonography using a 21-gauge needle on a 20-mL
Focal FDG uptake on PET/CT Figure 1
Focal FDG uptake on PET/CT. 54 year old female with 
breast cancer. The 18F-FDG PET/CT revealed focal uptake 
with SUV of 7.6. The patients was performed total thyroidec-
tomy with a final diagnosis of papillary thyroid carcinoma.World Journal of Surgical Oncology 2009, 7:63 http://www.wjso.com/content/7/1/63
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syringe under US guidance. A cytology diagnosis was
made by experienced cytopathologists. A total thyroidec-
tomy was performed in patients with a malignant neo-
plasm diagnosed by the FNA cytology. Patients with
indeterminate nodules on the FNA cytology underwent
frozen biopsy sampling during surgery; the type of opera-
tion was dependent on the results of the frozen biopsy.
Statistics
The statistical analysis was performed using the SPSS
(SPSS, Inc., Chicago, IL, USA) software package. A Chi-
square test was used to determine the prevalence differ-
ence of incidentally found thyroid lesions on the FDG-
PET/CT according to gender. A 95% confidence interval
was calculated. An independent T-test and the Mann-
Whitney U test were performed to compare benign thy-
roid lesions and malignant thyroid lesions. A receiver-
operating-characteristic (ROC) curve analysis was done to
differentiate benign from malignant lesions. Spearman's
rank correlation was used to assess the relationship
between the SUVmax and the diameter of the thyroid can-
cer. P values < 0.05 were considered statistically signifi-
cant. Numeric data were expressed as mean ± standard
deviation (SD).
Results
Three thousand three hundred seventy nine patients
(1,484 men, 1,895 women) underwent FDG-PET/CT. In
2,713 patients undergoing FDG-PET/CT for known or sus-
pected cancer, the primary site of malignancy was 893 suf-
fered from breast cancer, 428 from head and neck cancers
excluding thyroid cancer, 311 from gastrointestinal can-
cers, 306 from lung cancer, 297 from gynecologic cancers,
163 from lymphomas, 159 from hepatobiliary cancers,
132 from others, and 24 from metastases of unknown pri-
mary origin (Table 1). Of 3,379 patients undergoing FDG-
PET/CT, 285 (8.4%) patients were identified as having
incidentally found thyroid lesions on the FDG-PET/CT.
One hundred thirty-three (3.9%) patients had focal thy-
roid uptake and 152 (4.5%) patients had diffuse thyroid
uptake. Of 285 patients, there were 64 men and 221
women. The prevalence of incidentally found thyroid
lesions on FDG-PET/CT was higher in women than in
men (11.7% vs. 4.3%; odds ratio = 2.9, 95% CI 2.2–3.9, p
< 0.0001). The prevalence of incidentally found thyroid
lesions, on FDG-PET/CT, in patients being screened for
Diffuse FDG uptatake on PET/CT Figure 2
Diffuse FDG uptatake on PET/CT. 53 year old male. The 
18F-FDG PET/CT revealed diffuse uptake with SUV of 3.8. 
The sonographic features of the thyroid gland were strongly 
suggestive of the presence of thyroiditis.
Table 1: Location of primary lesion in patients with incidentally found thyroid lesions on 18F-FDG PET/CT.
Primary lesion Primary diagnosis
(n = 3,379)
FDG uptake on PET/CT
(n = 285)
Malignancy
(n = 23)
Breast 893 97 7
Gastrointestinal 311 25 4
Gynecologic 297 31 3
Lung 306 21 2
Lymphoma 163 19 1
Hepatobiliary 159 8 1
Head and Neck 428 17 0
Others 132 6 0
Unknown malignancy 24 3 0
Cancer screening 666 58 5
FDG; fluorodeoxyglucose (FDG)
PET/CT; Positron emission tomography (PET)/Computed tomography (CT)World Journal of Surgical Oncology 2009, 7:63 http://www.wjso.com/content/7/1/63
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cancer (58/666; 8.7%) was similar to that of patients with
suspected or known cancer (227/2,713; 8.4%).
Patients with focal thyroid uptake on FDG-PET/CT
Among 133 patients with incidental focal thyroid uptake
on the FDG-PET/CT, 68 (51.1%) patients underwent thy-
roid US. Among 68 patients, 49 (72%) patients under-
went US-guided FNA. Sixty-five patients did not undergo
thyroid US because of patient refusal, loss to clinical fol-
low-up or advanced stage of the underlying primary
malignancy. Nineteen patients who did not undergo FNA
had benign findings on US. Of 19 patients, 3 patients
become lost to follow up, 15 patients also had benign
findings at follow-up US. One patient die of cervical can-
cer. The FNA results were as follows: benign in 25 patients
(51%), malignant in 17 patients (34.7%), and indetermi-
nate in seven patients (14.3%). Sixteen patients with a
cytological diagnosis of a malignant neoplasm underwent
operative intervention, and the postoperative pathology
diagnosis confirmed the preoperative diagnosis. One
patient with a cytological diagnosis of a malignant neo-
plasm was lost to follow-up. Of 7 patients with cytological
diagnosis of an indeterminate nodule, 5 patients under-
went operative intervention, one patient did not undergo
follow up US and one patient become lost to follow up.
Among 5 patients who underwent operative intervention,
papillary carcinomas were found in three patients, follic-
ular carcinoma in one patient and nodular hyperplasia in
one patient.
Patients with diffuse thyroid uptake on FDG-PET/CT
Among 152 patients with diffuse thyroid uptake on the
FDG-PET/CT, 31 (20.4%) patients underwent thyroid US.
US findings showed thyroiditis or diffuse goiter in 14
(45.2%) patients, a benign-looking nodule in 10 (32.2%)
patients, an indeterminate nodule in four (12.9%)
patients, and normal findings in three (9.7%) patients. A
FNA was performed in four patients with an indetermi-
nate nodule on US. Benign lesions were found in two
patients. A malignant neoplasm and an indeterminate
lesion were found in the remaining two. Two patients
with a cytological diagnosis of a malignant neoplasm or
an indeterminate nodule underwent operative interven-
tion. A papillary cancer was found in one patient and a
follicular carcinoma was found in the other patient.
Characteristics of patients with a malignancy on the FNA 
or pathology
In 23 patients, the diagnosis of a malignancy was made by
histopathology. The malignancies were papillary carcino-
mas in 21 patients and follicular carcinomas in two
patients. The patients included 17 women and 6 men with
a mean age 53.5 ± 11.0 (range 47–72) years and 52.9 ±
10.8 (range 34–67) years, respectively. Twenty-two
patients underwent a total thyroidectomy. One patient
was lost to follow up. Focal uptake was significantly asso-
ciated with a higher prevalence of cancer when compared
to patients with diffuse uptake (P = 0.009) (Table 2). The
average value of SUVmax of malignant thyroid lesions was
significantly higher than that of benign thyroid lesions.
(Fig. 3) There was no correlation between the SUVmax and
the diameter of the benign lesion (Spearman r = 0.179,
95% -0.15 – 0.47, P = 0.271) There was a significant cor-
relation between the SUVmax and the diameter of the can-
cer (Spearman r = 0.776, 95% CI 0.50–0.91, P = 0.0001)
(Fig. 4). When the ROC curve and SUVmax value for differ-
entiating benign from malignant lesions were used, the
cut-off value for the SUVmax was 3.5 from the ROC curve
based on the present study. The sensitivity was 80.0% and
the specificity was 66.1% (Fig. 5)
Discussion
Our result showed that incidentally found thyroid lesions
including diffuse or focal FDG uptake on the FDG-PET/CT
occurred with a prevalence of 8.4% (285/3379), which is
higher than reported previously using FDG-PET [5,15].
The prevalence of focal FDG uptake in the thyroid gland
was also high in comparison with previous reports
[5,8,9,15]. The use of the FDG-PET/CT combination may
contribute to identifying thyroid uptake. Diffuse FDG
uptake in the thyroid gland is associated with benign con-
ditions such as thyroiditis, nodular goiter and Graves' dis-
ease [16-18]. In the present study, most ultrasound
examinations of patients with diffuse FDG uptake in thy-
roid gland showed benign disease such as thyroiditis and
multinodular goiter.
SUVmax of benign and malignant thyroid lesions on PET/CT Figure 3
SUVmax of benign and malignant thyroid lesions on 
PET/CT. Side by side box plots of SUVmax by groups. Statis-
tically significant differences was found in SUVmax between 
benign lesions and malignant lesions (P < 0.001).
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Incidentally found thyroid lesions have become an
important part of clinical practice. Many patients are inci-
dentally discovered during radiological imaging studies
for nonthyroidal disease or as part of a health screening
program. Ultrasound is the most sensitive diagnostic
modality for differentiating benign from malignant
lesions. There are no specific findings to suspect malig-
nancy on CT and MRI unless there is invasion into adja-
cent structures. Even though FDG-PET/CT is gradually
being used more frequently for cancer staging, localiza-
tion and surveillance of known cancers or cancer screen-
ing, there are no definitive findings for the diagnosis of
thyroid cancer. In our study, the cancer prevalence of
patients with incidentally found thyroid lesions on FDG-
PET/CT was 23.2% (23/99), which was lower than
reported in previous studies [1,5,9]. The cancer prevalence
with focal uptake on the FDG-PET/CT was 30.9% (21/68),
still lower than previous studies. However, that risk for a
malignancy, in those patients with focal uptake on the
FDG-PET/CT, is high and additional work up is needed in
these patients. Some authors have suggested that the SUV-
maxon the FDG-PET/CT might be useful to differentiate
benign from malignant thyroid lesions [8,9,19]. Kang et al
[8] reported that the average SUVmaxof malignant lesions
(16.5 ± 4.7) was significantly higher than that of benign
lesions (6.5 ± 3.8), whereas others reported that there was
no difference in the SUVmax between benign and malig-
nant lesions [5,15]. Our study showed that malignant thy-
roid lesions had a significantly higher SUVmax than benign
thyroid lesions. The pattern of uptake in the thyroid gland
on FDG-PET/CT was noted to be useful in differentiating
the patients with a malignancy. Focal uptake on the FDG-
PET/CT significantly correlated with an increased risk of
malignancy in comparison with a diffuse uptake. These
findings are similar to the results documented by other
reports [8,15].
The advantages of the FDG-PET/CT over FDG-PET include
anatomic localization of focal uptake and evaluation of
CT characteristics of the thyroid lesions detected on the
FDG-PET/CT. Choi et al [1] reported improved accuracy
for characterizing thyroid nodules on the FDG-PET/CT
using CT attenuation. Yi et al [20] also reported that four
malignant nodules had low attenuation on CT images.
However, CT could not definitively discriminate a benign
from a malignant nodule. The gold standard for diagnos-
ing a benign versus a malignant thyroid nodule is ultra-
sonography and fine needle aspiration biopsy. The CT can
help detect a focal thyroid nodule in patients with or with-
out mild FDG uptake.
In this study, the prevalence of incidentally found thyroid
lesions in suspected or known cancer patients on the
FDG-PET/CT was similar to that of patients receiving scan-
ning for health screening. Furthermore, the prevalence of
histologically proven thyroid malignancy was not differ-
ent between these two groups. Our results are not consist-
ent with a previous report [1]. Our results suggest that the
prevalence of incidentally found thyroid lesions is similar
in patients with known cancer and in the general popula-
tion. In addition, the primary location of a known or sus-
Correlation between SUVmax and cancer size Figure 4
Correlation between SUVmax and cancer size. Spear-
man r test was performed to find correlation between SUV-
max and thyroid cancer size. (Spearman r = 0.776, 95% 
confidence interval 0.50–0.91, P = 0.0001).
Size of cancer (mm)
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ROC curve to differentiate between benign and 
malignant lesions on PET/CT.
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pected cancer showed no significant difference of the
prevalence of incidentally found thyroid lesions on the
FDG-PET/CT.
The FDG-PET/CT has no a clear role in the preoperative
evaluation for differentiated thyroid cancer patients.
Mitchell et al [19] enrolled 31 patients with thyroid nod-
ules and demonstrated that the sensitivity and specificity
of FDG-PET/CT were 60% and 91%. The positive predic-
tive value and negative predictive value of the FDG-PET/
CT was 75% and 83%. Jeong HS et al [21] showed that the
FDG-PET/CT did not provide any additional benefit over
either the US or the contrast-enhanced CT for cervical
lymph node metastases in patients with papillary thyroid
cancer, because of the relatively low levels of glucose
metabolism. Our study showed that the sensitivity and
specificity of the FDG-PET/CT were 80.0% and 66.1%,
respectively, and that the FDG-PET/CT did not provide
information, preoperatively, on cervical lymph node
metastases in three patients with postoperatively proven
cervical lymph node metastasis of thyroid cancer. The
clinical significance of preoperative FDG-PET/CT for dif-
ferentiated thyroid cancer requires further investigation.
The main limitation of this study was the retrospective
analysis. Forty percent of patients who had incidentally
identified focal uptake by thyroid lesions on the FDG-
PET/CT did not have further evaluation. In the majority of
these patients, the extent of the primary disease did not
allow for a meaningful investigation of the incidentally
found thyroid lesions by FDG-PET/CT. Another limita-
tion was the small number of patients with incidentally
found thyroid lesions on the FDG-PET/CT and histologi-
cally proven thyroid nodules. Additional investigation
with a larger patient sample and a prospective study
design are needed for further study of this issue.
In patients with incidentally found thyroid lesions on
FDG-PET/CT, the prevalence of malignancy is 23.2%. The
prevalence in cancer screening subjects and in patients
with suspected and known cancer was similar. The factors
that were related with an increased risk of a malignancy
were focal FDG uptake on the FDG-PET/CT and a high
SUVmax. The presence of risk factors such as a focal FDG
uptake and a high SUVmax. on the FDG-PET/CT warrant
ultrasonography and fine needle aspiration biopsy.
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